KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	trifluridine/tipiracil Sensitive: B - Late Trials trifluridine / tipiracil Sensitive : B	trifluridine/tipiracil Sensitive: B - Late Trials trifluridine / tipiracil Sensitive : B
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	selumetinib Sensitive: B - Late Trials selumetinib Sensitive : B	selumetinib Sensitive: B - Late Trials selumetinib Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B

KRAS mutation

Associations